FDA Draft Guidance for Industry Action Level for Arsenic in Apple Juice
标准简介
Draft Guidance for Industry Action Level for Arsenic in Apple Juice [附网盘链接]是FDA发布的FDA标准,适用于U.S。标准截图
![Draft Guidance for Industry Action Level for Arsenic in Apple Juice [附网盘链接]](/img/202109141037250pr6c.jpg)
标准文档说明
标准文档类型为Draft Guidance for Industry Action Level for Arsenic in Apple Juice [附网盘链接]高清PDF版本(文字版),标准文档内可进行搜索,可以复制原文,可粘贴。标准部分原文
Draft-Not for Implementation 1
Guidance for Industry Arsenic in Apple Juice: Action Level This draft guidance, when finalized, will represent the Food and Drug Administration’s (FDA’s) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the telephone number listed on the title page of this guidance. I. Introduction This draft guidance document provides information to manufacturers on the action level for inorganic arsenic in apple juice that FDA considers protective of human health and achievable with the use of good manufacturing practices. FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required. II. Background Arsenic is an element that occurs in the environment from both natural and anthropogenic sources including erosion of arsenic-containing rocks, volcanic eruptions, contamination from 2
mining and smelting ores, and previous or current use of arsenic-containing pesticides (Ref. 1). Arsenic is found in both inorganic and organic forms (together referred to as total arsenic), and inorganic arsenic is generally considered more toxic than organic arsenic (Ref. 2). Consumption of inorganic arsenic has been associated with cancer, skin lesions, developmental effects, cardiovascular disease, neurotoxicity, and diabetes in humans (Ref. 2). In recent assessments, the Joint Food and Agriculture Organization/World Health Organization (FAO/WHO) Expert 1
This guidance has been prepared by the Division of Plant and Dairy Food Safety, Office of Food Safety, in the Center for Food Safety and Applied Nutrition at the U.S. Food and Drug Administration. 2
Generally, it is not possible for FDA to identify the source of arsenic in food, including apple juice, when found. Therefore, for purposes of this guidance FDA is not distinguishing the presence of arsenic that may be due to prior pesticide use, such that the residues are pesticide chemical residues subject to a tolerance or tolerance exemption by EPA under section 408 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 346a)), or other environmental contamination. 3
网盘链接
百度网盘:https://pan.baidu.com/s/1oFvDVCBiUO4OnAzRahYg8Q
提取码:jifn
【温馨提示】大资料ISO是提供信息发布的专业信息类网站,所有内容均由用户发布,不代表本站观点,本站亦不存储所涉及的文件及资料。如有【免费资料】以及【付费资料】,请用户根据自己的需求,自行判断是否需要获取。如有交易诈骗、内容侵权可发送邮件至kf@dzl100.com,我们审查后若发现情况属实,会立即对相关内容进行删除处理。
加载用时:69.9355 毫秒
相关评论
相关文章
-
FDA Draft Guidance for Industry Action Level for Arsenic in Apple Juice
Draft Guidance for Industry Action Level for Arsenic in Apple Juice [附网盘链接]是FDA于不久前发布的FDA标准,适用于U.S。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Expanded Access to Investigational Drugs for Treatment Use - Questions and Answers
Expanded Access to Investigational Drugs for Treatment Use - Questions and Answers[附网盘链接]是Food&Drug Administration于不久前发布的FDA标准,适用于U.S。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Exculpatory Language in Informed Consent
Exculpatory Language in Informed Consent[附网盘链接]是FDA于不久前发布的FDA标准,适用于美国。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Allowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products
Allowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products[附网盘链接]是Food And Drug Administration于不久之前发布的FDA标准,适用于US。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Adverse Accreditation Decisions, SuspensionRevocation of Certificates, or Patient and Physician Notification Orders Draft
Adverse Accreditation Decisions, SuspensionRevocation of Certificates, or Patient and Physician Notification Orders Draft[附网盘链接]是Food And Drug Administration于不久之前发布的FDA标准,适用于United States。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
CVM GFI #185 (VICH GL43) Target Animal Safety for Veterinary Pharmaceutical Products.pdf[网盘链接]
GFI #185 (VICH GL43) Target Animal Safety for Veterinary Pharmaceutical Products.pdf是于发布的标准,适用于。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances
Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances[附网盘链接]是FDA于过去发布的FDA标准,适用于美国。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry
Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry[附网盘链接]是FDA于过去发布的FDA标准,适用于美国。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Assay Migration Studies for In Vitro Diagnostic Devices Guidance for Industry and FDA Staff
Assay Migration Studies for In Vitro Diagnostic Devices Guidance for Industry and FDA Staff[附网盘链接]是FDA于过去发布的FDA标准,适用于United States。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products — Content and Format
Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products — Content and Format[附网盘链接]是Food And Drug Administration于当前发布的FDA标准,适用于United States。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Chronic Hepatitis D Virus Infection Developing Drugs for Treatment Guidance for Industry
Chronic Hepatitis D Virus Infection Developing Drugs for Treatment Guidance for Industry[附网盘链接]是Food&Drug Administration于当前发布的FDA标准,适用于United States。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Converting Units of Measure for Folate, Niacin, and Vitamins A, D, and E on the Nutrition and Supplement Facts Labels
Converting Units of Measure for Folate, Niacin, and Vitamins A, D, and E on the Nutrition and Supplement Facts Labels[附网盘链接]是Food And Drug Administration于不久前发布的FDA标准,适用于US。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Coronary Drug-Eluting Stents — Nonclinical and Clinical Studies -Companion Document
Coronary Drug-Eluting Stents — Nonclinical and Clinical Studies -Companion Document[附网盘链接]是FDA于当前发布的FDA标准,适用于美国。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Exemption and Exclusion from Certain Requirements of the Drug Supply Chain Security Act During the COVID-19 Public Health Emergency
Exemption and Exclusion from Certain Requirements of the Drug Supply Chain Security Act During the COVID-19 Public Health Emergency[附网盘链接]是Food And Drug Administration于当前发布的FDA标准,适用于United States。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Compliance Policy for the Quantity of Bioavailability and Bioequivalence Samples Retained Under 21 CFR 320.38(c)
Compliance Policy for the Quantity of Bioavailability and Bioequivalence Samples Retained Under 21 CFR 320.38(c)[附网盘链接]是FDA于不久前发布的FDA标准,适用于U.S。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。